{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T08:41:10Z","timestamp":1793868070569,"version":"4.6.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"Netherlands Organisation for Health Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019472","name":"Stichting Kwaliteitsgelden Medisch Specialisten","doi-asserted-by":"publisher","award":["Z69118327"],"award-info":[{"award-number":["Z69118327"]}],"id":[{"id":"10.13039\/100019472","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.euo.2025.11.002","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T04:58:04Z","timestamp":1764392284000},"page":"571-580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Extending Current Guideline-recommended Prostate-specific Antigen Density Thresholds for Improving Benefit\/Harm Balance in Risk-based Magnetic Resonance Imaging\u2013directed Prostate Cancer Diagnosis, from the Community-based Multicentre MR-PROPER Study"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6120-3162","authenticated-orcid":false,"given":"Anne M.A.","family":"Prinsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo M.","family":"Wagensveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Osses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter M.","family":"Groenendijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank M.","family":"Zijta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn B.","family":"Busstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rociu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelle O.","family":"Barentsz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P. Michiel","family":"Sedelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berber","family":"Arbeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ton","family":"Roeleveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remy","family":"Geenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Koeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent C.","family":"Cappendijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjoerd","family":"Klaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"van der Lely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tineke","family":"Wolters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maicle R.","family":"Leter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk G.","family":"van der Poel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn W.T.P.J.","family":"Heijmink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos","family":"Immerzeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost A.P.","family":"Leijte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joep G.H.","family":"van Roermund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razvan L.","family":"Miclea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Planken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 N.","family":"Vis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igle J.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper","family":"Tijsterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derk","family":"Wolterbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoesjka","family":"Claessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Nederend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris H.","family":"Bangma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique J.","family":"Roobol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiaan","family":"Remmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick C.N.","family":"van den Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diederik M.","family":"Somford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9804-0603","authenticated-orcid":false,"given":"Ivo G.","family":"Schoots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.11.002_b0005","unstructured":"Cornford P, Tilki D, van den Bergh RCN, et al. EAU \u2013 EANM \u2013 ESTRO \u2013 ESUR \u2013 ISUP \u2013 SIOG guidelines on prostate cancer. 2024."},{"key":"10.1016\/j.euo.2025.11.002_b0010","unstructured":"NICE. NICE guideline NG131. Prostate cancer: diagnosis and management. 2019. Last updated 15 December 2021."},{"key":"10.1016\/j.euo.2025.11.002_b0015","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.11.002_b0020","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.eururo.2021.07.024","article-title":"Prostate-specific antigen testing as part of a risk-adapted early detection strategy for prostate cancer: European Association of Urology position and recommendations for 2021","volume":"80","author":"Van Poppel","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.11.002_b0025","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.eururo.2022.03.003","article-title":"A prospective multicenter comparison study of risk-adapted ultrasound-directed and magnetic resonance imaging\u2013directed diagnostic pathways for suspected prostate cancer in biopsy-na\u00efve men","volume":"82","author":"Wagensveld","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.11.002_b0030","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41391-022-00579-6","article-title":"The role of PSA density in the MRI pathway for prostate cancer diagnostics","volume":"26","author":"Cash","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2025.11.002_b0035","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1007\/s00330-021-08407-6","article-title":"Risk-based MRI-directed diagnostic pathway outperforms non-risk-based pathways in suspected prostate cancer biopsy-na\u00efve men: a large cohort validation study","volume":"32","author":"Bittencourt","year":"2022","journal-title":"Eur Radiol"},{"key":"10.1016\/j.euo.2025.11.002_b0040","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.euf.2022.10.002","article-title":"Prostate-specific antigen density cutoff of 0.15\u00a0ng\/ml\/cc to propose prostate biopsies to patients with negative magnetic resonance imaging: efficient threshold or legacy of the past?","volume":"9","author":"Pellegrino","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2025.11.002_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euros.2022.06.006","article-title":"Implications of the European Association of Urology recommended risk assessment algorithm for early prostate cancer detection","volume":"43","author":"Isra\u00ebl","year":"2022","journal-title":"Eur Urol open Sci"},{"key":"10.1016\/j.euo.2025.11.002_b0050","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system","volume":"40","author":"Epstein","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.euo.2025.11.002_b0055","doi-asserted-by":"crossref","DOI":"10.2214\/AJR.24.32588","article-title":"MRI in prostate cancer screening: a review and recommendations, from the AJR special series on screening","volume":"225","author":"Schoots","year":"2025","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.euo.2025.11.002_b0060","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2025.05.038","article-title":"Magnetic resonance imaging\u2013based biopsy strategies in prostate cancer screening: a systematic review","volume":"88","author":"Schoots","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.11.002_b0065","doi-asserted-by":"crossref","first-page":"4747","DOI":"10.3390\/cancers14194747","article-title":"Magnetic resonance imaging-based predictive models for clinically significant prostate cancer: a systematic review","volume":"14","author":"Triquell","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.euo.2025.11.002_b0070","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1148\/radiol.2021204112","article-title":"Avoiding unnecessary biopsy: MRI-based risk models versus a PI-RADS and PSA density strategy for clinically significant prostate cancer","volume":"300","author":"Deniffel","year":"2021","journal-title":"Radiology"},{"key":"10.1016\/j.euo.2025.11.002_b0075","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/bju.15277","article-title":"Risk-adapted biopsy decision based on prostate magnetic resonance imaging and prostate-specific antigen density for enhanced biopsy avoidance in first prostate cancer diagnostic evaluation","volume":"127","author":"Schoots","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.11.002_b0080","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/bjr\/tqad027","article-title":"Risk stratification of prostate cancer with MRI and prostate-specific antigen density-based tool for personalized decision making","volume":"97","author":"Rajendran","year":"2023","journal-title":"Br J Radiol"},{"key":"10.1016\/j.euo.2025.11.002_b0085","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.euo.2018.09.001","article-title":"Prebiopsy biparametric magnetic resonance imaging combined with prostate-specific antigen density in detecting and ruling out Gleason 7\u201310 prostate cancer in biopsy-na\u00efve men","volume":"2","author":"Boesen","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.11.002_b0090","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.euo.2019.08.008","article-title":"Prebiopsy IMPROD biparametric magnetic resonance imaging combined with prostate-specific antigen density in the diagnosis of prostate cancer: an external validation study","volume":"3","author":"Knaapila","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.11.002_b0095","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.euo.2020.08.014","article-title":"Combined use of prostate-specific antigen density and magnetic resonance imaging for prostate biopsy decision planning: a retrospective multi-institutional study using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD)","volume":"4","author":"Falagario","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.11.002_b0100","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.eururo.2018.11.023","volume":"75","author":"van der Leest","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.11.002_b0105","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.eururo.2020.02.009","article-title":"Radical prostatectomy or observation for clinically localized prostate cancer: extended follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT)","volume":"77","author":"Wilt","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.11.002_b0110","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.euo.2022.07.004","article-title":"Active surveillance for intermediate-risk prostate cancer: a systematic review, meta-analysis, and metaregression","volume":"5","author":"Baboudjian","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.11.002_b0115","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.28320","article-title":"Surgical delay and pathological outcomes for clinically localized high-risk prostate cancer","volume":"3","author":"Xia","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euo.2025.11.002_b0120","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1097\/JU.0000000000001601","article-title":"Systematic review of time to definitive treatment for intermediate risk and high risk prostate cancer: are delays associated with worse outcomes?","volume":"205","author":"Nguyen","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.11.002_b0125","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1007\/s00345-020-03402-w","article-title":"Timing and delay of radical prostatectomy do not lead to adverse oncologic outcomes: results from a large European cohort at the times of COVID-19 pandemic","volume":"39","author":"Diamand","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2025.11.002_b0130","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1097\/JU.0000000000001089","article-title":"Delayed radical prostatectomy is not associated with adverse oncologic outcomes: implications for men experiencing surgical delay due to the COVID-19 pandemic","volume":"204","author":"Ginsburg","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.11.002_b0135","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.urology.2022.09.007","article-title":"MRI vs transrectal ultrasound to estimate prostate volume and PSAD: impact on prostate cancer detection","volume":"171","author":"Choe","year":"2023","journal-title":"Urology"},{"key":"10.1016\/j.euo.2025.11.002_b0140","doi-asserted-by":"crossref","first-page":"264","DOI":"10.5489\/cuaj.3236","article-title":"Prostate volume estimations using magnetic resonance imaging and transrectal ultrasound compared to radical prostatectomy specimens","volume":"10","author":"Paterson","year":"2016","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.euo.2025.11.002_b0145","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.urolonc.2012.03.002","article-title":"Comparison of prostate volume measured by transrectal ultrasound and magnetic resonance imaging: is transrectal ultrasound suitable to determine which patients should undergo active surveillance?","volume":"31","author":"Weiss","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2025.11.002_b0150","doi-asserted-by":"crossref","unstructured":"Bj\u00f6rnebo L, Discacciati A, Abbadi A, et al. Prostate-specific antigen density as a selection tool before magnetic resonance imaging in prostate cancer screening: an analysis from the STHLM3MRI randomized clinical trial. Eur Urol Focus. In press. https:\/\/doi.org\/10.1016\/J.EUF.2025.06.008.","DOI":"10.1016\/j.euf.2025.06.008"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125002901?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125002901?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T20:42:49Z","timestamp":1783197769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125002901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2588931125002901"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.11.002","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extending Current Guideline-recommended Prostate-specific Antigen Density Thresholds for Improving Benefit\/Harm Balance in Risk-based Magnetic Resonance Imaging\u2013directed Prostate Cancer Diagnosis, from the Community-based Multicentre MR-PROPER Study","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}